150 related articles for article (PubMed ID: 34312126)
1. Presumed complement-mediated, checkpoint inhibitor-induced, thrombotic microangiopathy in a patient with metastatic melanoma.
Muniz TP; Patriquin CJ; Saibil SD
BMJ Case Rep; 2021 Jul; 14(7):. PubMed ID: 34312126
[TBL] [Abstract][Full Text] [Related]
2. Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma.
Gao CA; Weber UM; Peixoto AJ; Weiss SA
J Immunother Cancer; 2019 Oct; 7(1):262. PubMed ID: 31623673
[TBL] [Abstract][Full Text] [Related]
3. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
Tan I; Malinzak M; Salama AKS
J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
[TBL] [Abstract][Full Text] [Related]
4. Case Report: Thrombotic-Thrombocytopenic Purpura Following Ipilimumab and Nivolumab Combination Immunotherapy for Metastatic Melanoma.
Mullally WJ; Cooke FJ; Crosbie IM; Kumar S; Abernethy VE; Jordan EJ; O'Connor M; Horgan AM; Landers R; Naidoo J; Calvert PM
Front Immunol; 2022; 13():871217. PubMed ID: 35514990
[TBL] [Abstract][Full Text] [Related]
5. A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab.
Olson DJ; Rajagopal P; Tjota MY; Venkataraman G; Luke JJ; Gajewski TF
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169870
[TBL] [Abstract][Full Text] [Related]
6. Metastatic lung adenocarcinoma- associated thrombotic microangiopathy in a renal transplant recipient.
Vilayur E; de Malmanche J; Trevillian P; Ferreira D
BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30567242
[TBL] [Abstract][Full Text] [Related]
7. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report.
Appelbaum J; Wells D; Hiatt JB; Steinbach G; Stewart FM; Thomas H; Nghiem P; Kapur RP; Thompson JA; Bhatia S
J Immunother Cancer; 2018 Aug; 6(1):82. PubMed ID: 30170630
[TBL] [Abstract][Full Text] [Related]
8. Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors.
Cao Y; Afzal MZ; Gutmann EJ; Shirai K
Melanoma Res; 2024 Feb; 34(1):70-75. PubMed ID: 37830935
[TBL] [Abstract][Full Text] [Related]
9. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand.
Fox LC; Cohney SJ; Kausman JY; Shortt J; Hughes PD; Wood EM; Isbel NM; de Malmanche T; Durkan A; Hissaria P; Blombery P; Barbour TD
Nephrology (Carlton); 2018 Jun; 23(6):507-517. PubMed ID: 29419916
[TBL] [Abstract][Full Text] [Related]
10. Autoimmune polyradiculitis due to combination immunotherapy with ipilimumab and nivolumab for the treatment of metastatic melanoma.
Lasocki A; Smith K
J Clin Neurosci; 2020 Apr; 74():240-241. PubMed ID: 31983645
[TBL] [Abstract][Full Text] [Related]
11. Recurrent audiovestibular dysfunction and associated neurological immune-related adverse events in a melanoma patient treated with nivolumab and ipilimumab.
Choi JS; Chen M; McQuade JL; Appelbaum E; Gidley PW; Nader ME
Head Neck; 2020 Nov; 42(11):E35-E42. PubMed ID: 32888241
[TBL] [Abstract][Full Text] [Related]
12. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
13. Acute pancreatitis without abdominal pain induced by administration of nivolumab and ipilimumab.
Yamamoto K; Oka K; Son R; Honda H; Sakae H; Hasegawa K; Horiguchi S; Kato H; Yamasaki O; Otsuka F
Mod Rheumatol Case Rep; 2021 Jul; 5(2):425-430. PubMed ID: 33821775
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
15. Case Report: Fulminant Celiac Disease With Combination Immune Checkpoint Therapy.
Falade AS; Reynolds KL; Zubiri L; Deshpande V; Fintelmann FJ; Dougan M; Mooradian MJ
Front Immunol; 2022; 13():871452. PubMed ID: 35493494
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review.
Sise ME; Seethapathy H; Reynolds KL
Oncologist; 2019 Jun; 24(6):735-742. PubMed ID: 30902916
[TBL] [Abstract][Full Text] [Related]
17. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
18. Toxic epidermal necrolysis occurring with immune checkpoint inhibitors.
Gopee NH; Gourley AM; Oliphant TJ; Hampton PJ
Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941713
[TBL] [Abstract][Full Text] [Related]
19. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
20. Interstitial granulomatous dermatitis and concurrent immunotherapy associated encephalitis with nivolumab and ipilimumab.
Starling CT; Messer AA; Kleiman A; McQuade JL; Glitza IC; Torres-Cabala CA; Heberton M
Dermatol Online J; 2022 Mar; 28(2):. PubMed ID: 35670686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
